Targeted oxidative therapeutic formulation

1. A pharmaceutical formulation comprising:

peroxidic species or reaction products resulting from oxidation of an alkene by an oxygen-containing oxidizing agent, wherein the alkene has less than about 35 carbons;

a penetrating solvent;

a dye containing a chelated divalent or trivalent metal; and

an aromatic redox compound.

2. The pharmaceutical formulation of claim 1 , wherein the alkene comprises an open-chain unsaturated hydrocarbon, a monocyclic unsaturated hydrocarbon, or a bicyclic unsaturated hydrocarbon.

3. The pharmaceutical formulation of claim 1 , wherein the alkene comprises an open-chain unsaturated alcohol, a monocyclic unsaturated alcohol, or a bicyclic unsaturated alcohol.

4. The pharmaceutical formulation of claim 1 , wherein the alkene is an hydroxyl-contaning alkene.

5. The pharmaceutical formulation of claim 1 , wherein the alkene is in a liquid form, in a solution, or in a dispersion.

6. The pharmaceutical formulation of claim 1 , wherein the alkene comprises an isoprenoid.

7. The pharmaceutical formulation of claim 6 , wherein the isoprenoid comprises α-terpineol, citronellol, nerol, phytol, menthol, geraniol, geranylgeraniol, linalool, or famesol.

8. The pharmaceutical formulation of claim 6 , wherein the isoprenoid comprises myricene, citrillene, citral, pinene, or limonene.

9. The pharmaceutical formulation of claim 1 , wherein the alkene comprises fixed oil-, ester-, fatty acid-, or ether-containing olefin.

10. The pharmaceutical formulation of claim 1 , wherein the oxygen-containing oxidizing agent comprises singlet oxygen, oxygen in its triplet state, superoxide anion, periodate, hydroxyl radical, peroxide, or oxygen bound to a transition element.

11. The pharmaceutical formulation of claim 1 , wherein the oxygen-containing oxidizing agent comprises ozone.

12. The pharmaceutical formulation of claim 1 , wherein the penetrating solvent is a liquid, micelle membrane, emollient, plasma, or vapor.

13. The pharmaceutical formulation of claim 1 , wherein the penetrating solvent is dimethylsulfoxide.

14. The pharmaceutical formulation of claim 1 , wherein the penetrating solvent is polyvinylpyrrolidine or a pH-buffered saline.

15. The pharmaceutical formulation of claim 1 , wherein the penetrating solvent is aqueous solution, fats, sterols, lecithins, phosphatides, ethanol, propylene glycol, or methylsulfonylmethane.

16. The pharmaceutical formulation of claim 1 , wherein the dye can be activated by an energy.

17. The pharmaceutical formulation of claim 1 , wherein the dye comprises porphyrin or rose bengal.

18. The pharmaceutical formulation of claim 1 , wherein the dye comprises chlorophyllin, hemin, corrins, texaphrin, methylene blue, hematoxylin, eosin, erythrosin, lactoflavin, anthracene dye, hypericin, methylcholanthrene, neutral red, or fluorescein.

19. The pharmaceutical formulation of claim 16 , wherein the energy comprises photon or electroporation pulse.

20. The pharmaceutical formulation of claim 13 , wherein the energy comprises laser, ionizing radiation, phonon, electrical pulse, magnetic field, plasma pulse, gravitational pulse, or continuous flow excitation.

21. The pharmaceutical formulation of claim 1 , wherein the metal comprises iron.

22. The pharmaceutical formulation of claim 1 , wherein the metal comprises copper, manganese, tin, magnesium, or strontium.

23. The pharmaceutical formulation of claim 1 , wherein the aromatic redox compound comprises benzoquinone or naphthoquinone.

24. The pharmaceutical formulation of claim 1 further comprising an electron donor.

25. The pharmaceutical formulation of claim 24 , wherein the electron donor comprises ascorbic acid or a pharmaceutical salt thereof.

26. The pharmaceutical formulation of claim 24 , wherein the electron donor comprises plasma, electrical current or germanium sesquioxide.

27. A pharmaceutical formulation comprising:

peroxidic species or reaction products resulting from oxidation of a hydroxyl-containing alkene by a mixture of ozone and oxygen, wherein the hydroxyl-containing alkene has less than about 35 carbons;

a penetrating solvent;

a dye containing a chelated divalent or trivalent metal; and

an aromatic redox compound.

28. The pharmaceutical formulation of claim 27 , wherein the hydroxyl-containing alkene comprises an open-chain unsaturated alcohol, a monocyclic unsaturated alcohol, or a bicyclic unsaturated alcohol.

29. The pharmaceutical formulation of claim 27 , wherein the hydroxyl-containing alkene is in a liquid form, in a solution, or in dispersion.

30. The pharmaceutical formulation of claim 27 , wherein the hydroxyl-containing alkene comprises α-terpineol, citronellol, nerol, linalool, phytol, geraniol, perillyl alcohol, menthol, geranylgeraniol, or famesol.

31. The pharmaceutical formulation of claim 27 , wherein the penetrating solvent is a liquid, micelle membrane, emollient, plasma, or vapor.

32. The pharmaceutical formulation of claim 27 , wherein the penetrating solvent is dimethylsulfoxide.

33. The pharmaceutical formulation of claim 27 , wherein the penetrating solvent is polyvinylpyrrolidine or a pH-buffered saline.

34. The pharmaceutical formulation of claim 27 , wherein the penetrating solvent is aqueous solution, fats, sterols, lecithins, phosphatides, ethanol, propylene glycol, or methylsulfonylmethane.

35. The pharmaceutical formulation of claim 27 , wherein the dye comprises porphyrin or rose bengal.

36. The pharmaceutical formulation of claim 27 , wherein the dye comprises chlorophyllin, hemin, corrins, texaphrin, methylene blue, hematoxylin, eosin, erythrosin, lactoflavin, anthracene dye, hypericin, methylcholanthrene, neutral red, or fluorescein.

37. The pharmaceutical formulation of claim 27 , wherein the metal comprises iron.

38. The pharmaceutical formulation of claim 27 , wherein the metal comprises copper, manganese, tin, magnesium, or strontium.

39. The pharmaceutical formulation of claim 27 , wherein the aromatic redox compound comprises benzoquinone or naphthoquinone.

40. The pharmaceutical formulation of claim 27 further comprising an electron donor.

41. The pharmaceutical formulation of claim 40 , wherein the electron donor comprises ascorbic acid or a pharmaceutical salt thereof.

42. The pharmaceutical formulation of claim 40 , wherein the electron donor comprises plasma, electrical current or germanium sesquioxide.

43. A pharmaceutical formulation comprising:

peroxidic species or reaction products resulting from oxidation of a hydroxyl-containing alkene by a mixture of ozone and oxygen, wherein the hydroxyl-containing comprises α-terpineol, citronellol, nerol, linalool, phytol, geraniol, perillyl alcohol, menthol, geranylgeraniol or farnesol;

a penetrating solvent, wherein the penetrating solvent comprises dimethylsulfoxide, sterol, lecithin, propylene glycol, or methylsulfonylmethane;

a dye containing a chelated divalent or trivalent metal, wherein the dye comprises porphyrin, rose bengal, chlorophyllin, hemin, corrins, texaphrin, methylene blue, hematoxylin, eosin, erythrosin, lactoflavin, anthracene dye, hypericin, methylcholanthrene, neutral red, or fluorescein; and

an aromatic redox compound, wherein the redox compound comprises benzoquinone or naphthoquinone.

44. The pharmaceutical formulation of claim 43 , wherein the metal comprises iron, copper, manganese, tin, or magnesium.

45. The pharmaceutical formulation of claim 43 further comprising an electron donor.

46. The pharmaceutical formulation of claim 45 , wherein the electron donor comprises ascorbic acid or a pharmaceutical salt thereof.

47. The pharmaceutical formulation of claim 45 , wherein the electron donor comprises plasma, electrical current or germanium sesquioxide.